Latest Articlesddd
Prohost Letter #394 Part 1 Gilead - Some people sold Gilead’s (GILD) stock on Wednesday, March 23 …
Incyte (INCY) and Eli Lilly (LLY): The New England Journal of Medicine published detailed results of RA-BEACON — a pivotal …
The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 …
Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in …
It is an ingenuous decision made by investors who rushed to consider betrixaban Phase 3 APEX study a …
Amgen (AMGN) and UCB (Euronext Brussels: UCB) announced positive results from the BRIDGE pivotal Phase 3 placebo-controlled …
Published articles in peer review journals cited that pharmacologic inhibition of RORγt regulates Th17 signature gene expression …
Immunotherapy for Cancer Blueprint Medicines Blueprint Medicines (BPMC) entered into a worldwide collaboration and exclusive license agreement …
First therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a …
London, UK, 14 March 2016: GW Pharmaceuticals (GWPH), is a biopharmaceutical company focused on discovering, developing and …
The Diagnosed Dead Is Far from Dying Xoma (XOMA): Stock rallied following report announcing an upfront …
Of the Upcoming Game-Changing Actions THE EXPECTED FDA APPROVAL OF JAZZ DRUG DEFIBROTIDE On March 31, the FDA …
As we kept describing it, Illumina’s (ILMN) is the engine behind the biological revolution reflected in the current …
Prohost Letter #393 IMMUNOTHERAPY - PROHOST PORTFOLIO - NEW PICKS? - A Brief Reminder of the CAR T –TCR …
Preparing a Prohost Letter dedicated to immunotherapy and the firms that are behind the promising novel …
Agenus (AGEN) is a project in the making since the firm has decided to play an integral …
Exelixis’ (EXEL) quarterly results beat analysts’ expectations, which was the least of our concerns. The details of the …
Prohost Letter #392 February 28, 2016 - How could it be possible for any genius to make …
Baxalta (BXLT) and Precision BioSciences a genome editing company announced a global collaboration to develop a broad …
Recent Breakthrough Designated Products CANCER Acute Myeloid Leukemia PKC412 (midostaurin) developed by Novartis AG (NVS) is an oral, …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
